Portfolio

Based on current portfolio Esjay Pharma is expected to reach ca. 100 products by 2027 YE

Esjay Pharma Current Portfolio1

Number of Products at Year End

Esjay Pharma Portfolio
Granted CGT2 2 5 5
Potential CGT2 - 1 9
Paragraph IV - 1 4
  1. Cumulative number of products. Includes both approved products and ongoing project
  2. Competitive Generic Therapy designation. Numbers indicate the cumulative numbers

Esjay Pharma is expected to reach ca. 100 products based on current portfolio of approved products and ongoing projects

Portfolio consists of both Gx and OTC products

It is commercial since 2024 providing CMO services to several established public and private pharma companies

Given the expected number of products over the next 2-3 years several CDMO and Out-licensing opportunities exist both in the US and in international markets